showed that for high grade serous ovarian cancer, HR-deficient tumors presented more TILs, higher expression levels of programmed death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) and more putative neoantigen than HR-proficient ones (36). This evidence concerns the gene CD274 and ovarian serous adenocarcinoma.